title: Anti-tumor promoting activity of canventol and its synthetic analogs through inhibition of protein isoprenylation.
abstract: Canventol, a synthetic compound, is a new inhibitor of tumor promotion on mouse skin by okadaic acid. We previously reported that canventol acts by inhibiting both protein isoprenylation and tumor necrosis factor-alpha (TNF-alpha) release. In this study we examined the potencies of 10 newly synthesized canventol analogs through their effect on mevalonate metabolism, and then examined 3 representative analogs for inhibition of protein isoprenylation. Since canventol in vitro did not directly inhibit farnesyl protein transferase or geranylgeranyl protein transferase-I, the effects of canventol and its synthetic analogs on the fate of [3H]mevalonate in cells were studied. Canventol at 500 microM changed the ratio of newly synthesized sterols (cholesterol and lathosterol) to ubiquinones from 0.7 to 8.2 in NIH/3T3 cells which had previously been labeled with [3H]mevalonate, suggesting that the altered pattern of mevalonate metabolism is associated with inhibition of protein isoprenylation in the cells. We named this ratio the inhibition of protein isoprenylation index (IPI index). The 10 analogs showed a wide range of IPI indices. Two analogs, S3 and S9 had effects similar to, or stronger than, canventol. Three analogs, C44, C46 and C47, with lower IPI indices, inhibited tumor promotion on mouse skin slightly less than canventol itself did. This study shows that inhibition of protein isoprenylation in the cells, indicated by an increase in the IPI index, is a new biomarker for estimating inhibition of tumor promotion.
authors.affiliation: Saitama Cancer Center Research Institute, Saitama.
authors.forename: A
authors.initials: A
authors.lastname: Komori
authors.forename: S
authors.initials: S
authors.lastname: Okabe
authors.forename: M
authors.initials: M
authors.lastname: Suganuma
authors.forename: M A
authors.initials: MA
authors.lastname: Kerr
authors.forename: J
authors.initials: J
authors.lastname: Busch-Petersen
authors.forename: L M
authors.initials: LM
authors.lastname: Oh
authors.forename: J
authors.initials: J
authors.lastname: Zhuo
authors.forename: G S
authors.initials: GS
authors.lastname: Kannangara
authors.forename: X
authors.initials: X
authors.lastname: Zou
authors.forename: M A
authors.initials: MA
authors.lastname: Tius
authors.forename: H
authors.initials: H
authors.lastname: Fujiki
mesh_terms: D016475:3T3 Cells / Q000187:drug effects / Q000378:metabolism; D019883:Alkyl and Aryl Transferases; D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D002273:Carcinogens; D003511:Cyclohexanols / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D050356:Lipid Metabolism; D008798:Mevalonic Acid / Q000031:analogs & derivatives / Q000378:metabolism; D051379:Mice; D008815:Mice, Inbred Strains; D019319:Okadaic Acid; D017368:Protein Prenylation / Q000187:drug effects*; D012878:Skin Neoplasms / Q000139:chemically induced / Q000517:prevention & control*; D013261:Sterols / Q000096:biosynthesis; D014166:Transferases / Q000037:antagonists & inhibitors; D014451:Ubiquinone / Q000096:biosynthesis
chemical_list: D016588:Anticarcinogenic Agents; D002273:Carcinogens; D003511:Cyclohexanols; D004791:Enzyme Inhibitors; D013261:Sterols; D014451:Ubiquinone; C082453:canventol; D019319:Okadaic Acid; C015367:mevalonolactone; D014166:Transferases; D019883:Alkyl and Aryl Transferases; C084921:cis-isoprenyltransferase; D008798:Mevalonic Acid